Topical Cyclosporine-A for Management of Epiphora (NCT04637633) | Clinical Trial Compass
CompletedPhase 2/3
Topical Cyclosporine-A for Management of Epiphora
Kuwait12 participantsStarted 2020-08-15
Plain-language summary
to investigate the clinical outcomes and tolerances of Cyclosporine A (CsA) in treating epiphora in eyes with acquired punctum stenosis
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients of either sex
* had a diagnosis of epiphora that persisted more than three months both indoors and outdoors
* grade 0 punctal stenosis
* did not adequately respond to artificial tears, topical corticosteroids and topical antibiotics or in whom corticosteroids were discontinued due to their side effects.
Exclusion Criteria:
* congenital punctal obstruction
* edematous puncti
* allergic conjunctivitis
* history of dacryocystitis,
* inflammatory systemic diseases
* any previous chemotherapy treatment, and local irradiation.
* other causes of epiphora, lid laxity, entropion, and ectropion
* lid malposition, canalicular or nasolacrimal sac or duct obstruction
* previous eyelid or lacrimal drainage surgery
* untreated conjunctivitis or blepharitis